The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
Minimal residual illness, or MRD, testing might have the potential to supply peace of thoughts to survivors of breast most cancers, as a survivor and...
Dr. Vinayak Venkataraman, medical oncologist and director of Sarcoma Pathways at Dana-Farber Most cancers Institute in Boston, lately sat down with CURE...
The U.S. Meals and Drug Administration (FDA) has granted orphan drug designation to DPTX3186, an investigational remedy being developed by Dewpoint Therapeutics...
On Sept. 5, 2025, the U.S. Meals and Drug Administration (FDA) accepted Inlexzo (gemcitabine intravesical system) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive...
